# **Special Issue**

# Extracellular Vesicles: Biology and Emerging Therapeutic Opportunities

# Message from the Guest Editors

Extracellular vesicles (EVs) are secreted by all cell types and can be found in all body fluids. EVs are intensely discussed and studied as potential new diagnostic biomarkers, and their ability to act as a natural vector offers a unique platform for the development of a new class of therapeutics. For example, unmodified EVs derived from mesenchymal stromal cells have demonstrated beneficial therapeutic effects in multiple animal disease models, and additionally EVs can be engineered to display various targeting and therapeutic moieties and shuttle cargo over biological barriers. Despite those prospects, many EV-related aspects related to EV production, isolation, formulation, cargo and function as well as their subsequent therapeutic application are yet poorly defined. This Special Issue has the aim to summarize the state-of-the-art, and the latest findings published within the field, as well as to elucidate future directions.

## **Guest Editors**

Dr. Samir EL Andaloussi

Dr. Joel Nordin

Dr. André Görgens

Dr. Daniel W. Hagey

## **Deadline for manuscript submissions**

closed (28 February 2022)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/40794

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





# **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

